{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:06Z","timestamp":1786120326484,"version":"build-2736575974"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834b892d","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:56:09Z","timestamp":1317758169000},"page":"578-586","source":"Crossref","is-referenced-by-count":39,"title":["Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies"],"prefix":"10.1097","volume":"23","author":[{"given":"Nushmia Z.","family":"Khokhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR.","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer.","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy.","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/msb.2010.108","article-title":"A comprehensive map of the mTOR signaling network.","volume":"6","author":"Caron","year":"2010","journal-title":"Mol Syst Biol"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship.","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer.","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signaling.","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors.","volume":"27","author":"Menon","year":"2008","journal-title":"Oncogene"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/156800910791517172","article-title":"The mTOR pathway: a new target in cancer therapy.","volume":"10","author":"Ciuffreda","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives.","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOH.0b013e3282f3deaa","article-title":"Exploiting the mammalian target of rapamycin (mTOR) pathway in hematologic malignancies.","volume":"15","author":"Altman","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Global ARCC TrialTemsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"3rd, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J Clin Oncol"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"RECORD-1 Study GroupEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543784.17.11.1619","article-title":"Mechanism of action of rapalogues: the antiangiogenic hypothesis.","volume":"17","author":"Faivre","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R22-5-20210128","first-page":"1585","article-title":"Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms BJU I","volume":"104","author":"Mulders","year":"2009","journal-title":"nt"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/jco.2007.25.18_suppl.5034","article-title":"Phase III trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results meeting abstracts.","volume":"25","author":"Merchan","year":"2007","journal-title":"J Clin Oncol"},{"key":"R31-5-20210128","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1200\/jco.2009.27.15_suppl.5037","article-title":"Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma.","volume":"27","author":"Kroog","year":"2009","journal-title":"J Clin Oncol"},{"key":"R39-5-20210128","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1002\/cncr.25264","article-title":"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrentrefractory non small cell lung cancer.","volume":"116","author":"Ramalingam","year":"2010","journal-title":"Cancer"},{"key":"R40-5-20210128","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/JTO.0b013e3181ec1531","article-title":"Phase II trial of gefitinib and everolimus in advanced nonsmall cell lung cancer.","volume":"5","author":"Price","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R41-5-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"R47-5-20210128","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0b013e318155a439","article-title":"Eastern Cooperative Oncology Group (E1500)A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).","volume":"2","author":"Pandya","year":"2007","journal-title":"J Thorac Oncol"},{"key":"R48-5-20210128","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-10-0802","article-title":"Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.","volume":"16","author":"Tarhini","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R49-5-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"R50-5-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study GroupEverolimus for advanced pancreatic neuroendocrine tumors.","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"R52-5-20210128","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3816\/CBC.2006.n.047","article-title":"P, Abrial C, Tacca, et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.","volume":"7","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"R55-5-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdq350","article-title":"German Breast Group and Arbeitsgemeinschaft Gynakologische Onkologie-Brust investigatorsIntegrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.","volume":"22","author":"Von Minckwitz","year":"2011","journal-title":"Ann Oncol"},{"key":"R56-5-20210128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2007.10.003","article-title":"The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.","volume":"44","author":"Awada","year":"2008","journal-title":"Eur J Cancer"},{"key":"R58-5-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.critrevonc.2007.06.010","article-title":"Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.","volume":"64","author":"Gligorov","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"R59-5-20210128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.27.7814","article-title":"Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.","volume":"29","author":"Migliaccio","year":"2011","journal-title":"J Clin Oncol"},{"key":"R60-5-20210128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","article-title":"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.","volume":"177","author":"Esteva","year":"2010","journal-title":"Am J Pathol"},{"key":"R61-5-20210128","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinaseAKT signaling confers resistance to trastuzumab but not lapatinib.","volume":"9","author":"OBrien","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"R62-5-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","article-title":"Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pretreated patients with HER2-overexpressing metastatic breast cancer.","volume":"125","author":"Jerusalem","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R66-5-20210128","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus) in patients with recurrent endometrial carcinoma.","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"R68-5-20210128","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/jco.2008.26.15_suppl.5516","article-title":"A phase II study of temsirolimus (CCI-779) in patients with metastatic andor locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b.","volume":"26","author":"Oza","year":"2008","journal-title":"J Clin Oncol"},{"key":"R70-5-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2010.02.022","article-title":"A phase I study of weekly temsirolimus and topotecan in the treatment of advanced andor recurrent gynecologic malignancies.","volume":"117","author":"Temkin","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R78-5-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2009.02567.x","article-title":"Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature.","volume":"16","author":"Adriaensen","year":"2009","journal-title":"Eur J Neurol"},{"key":"R79-5-20210128","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"R80-5-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","article-title":"North American Brain Tumor Consortium and the National Cancer InstitutePhase II study of CCI-779 in patients with recurrent glioblastoma multiforme.","volume":"23","author":"Chang","year":"2005","journal-title":"Invest New Drugs"},{"key":"R81-5-20210128","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1158\/1078-0432.CCR-10-1453","article-title":"Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.","volume":"16","author":"Sarkaria","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R82-5-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/annonc\/mdq307","article-title":"Updating progress in sarcoma therapy with mTOR inhibitors.","volume":"22","author":"Blay","year":"2011","journal-title":"Ann Oncol"},{"key":"R84-5-20210128","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1200\/jco.2008.26.15_suppl.10519","article-title":"A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib resistant gastrointestinal stromal tumors (GIST).","volume":"26","author":"Dumez","year":"2008","journal-title":"J Clin Oncol"},{"key":"R85-5-20210128","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1200\/jco.2007.25.18_suppl.10076","article-title":"Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: update of phase II trial.","volume":"25","author":"Chawla","year":"2007","journal-title":"J Clin Oncol"},{"key":"R95-5-20210128","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"R96-5-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"R97-5-20210128","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R98-5-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"R101-5-20210128","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia.","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"R102-5-20210128","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.","volume":"15","author":"Perl","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R103-5-20210128","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R104-5-20210128","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase III study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R106-5-20210128","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.leukres.2009.01.039","article-title":"Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.","volume":"33","author":"Farag","year":"2009","journal-title":"Leuk Res"},{"key":"R107-5-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1470-2045(11)70028-6","article-title":"Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 12, open-label, dose-escalation study.","volume":"12","author":"Ghobrial","year":"2011","journal-title":"Lancet Oncol"},{"key":"R108-5-20210128","first-page":"428","article-title":"Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.","volume":"13","author":"Richard","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R109-5-20210128","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"key":"R110-5-20210128","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-10-0480","article-title":"Target of rapamycin signaling in leukemia and lymphoma.","volume":"16","author":"Vu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R111-5-20210128","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition.","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci Signal"},{"key":"R112-5-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway.","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"R113-5-20210128","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/13543784.2010.499121","article-title":"New inhibitors of the mammalian target rapamycin signaling pathway for cancer.","volume":"19","author":"Albert","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"R114-5-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2010.01.021","article-title":"Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.","volume":"17","author":"Hsieh","year":"2010","journal-title":"Cancer Cell"},{"key":"R115-5-20210128","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 andmTORC2.","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"R116-5-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00063030-200923020-00002","article-title":"Current status and challenges associated with targeting mTOR for cancer therapy.","volume":"23","author":"Dowling","year":"2009","journal-title":"BioDrugs"},{"key":"R117-5-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC12 kinase inhibitor.","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"R118-5-20210128","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R119-5-20210128","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","article-title":"Dual mTORC2mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.","volume":"17","author":"Altman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R120-5-20210128","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2010-05-285726","article-title":"Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.","volume":"116","author":"Hoang","year":"2010","journal-title":"Blood"},{"key":"R121-5-20210128","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/bjc.2011.83","article-title":"Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTENLKB1-deficient mice.","volume":"104","author":"Garcia-Martinez","year":"2011","journal-title":"Br J Cancer"},{"key":"R122-5-20210128","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.","volume":"30","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"R123-5-20210128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"R124-5-20210128","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-10-3126","article-title":"Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1mTORC2 inhibitors.","volume":"71","author":"Falcon","year":"2011","journal-title":"Cancer Res"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32834b892d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:28Z","timestamp":1786048048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201111000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834b892d","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}